SUBSEQUENT EVENTS	3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On May 6, 2025, as part of the Company’s ongoing efforts to preserve cash, the Board of Directors of the Company approved (i) the issuance of unregistered shares of the Company’s common stock representing an aggregate of approximately $3,750 in value to the members of MedTech in lieu of the three remaining annual $1,250 cash payments otherwise required under the MedTech Purchase Agreement on or about May 1st of each of 2025, 2026, and 2027; and (ii) an Amended and Restated Non-Employee Director Compensation Policy that increases the total director compensation from approximately $180 to $207 per year and provides for the payment of the remaining director compensation for 2025 in shares of restricted stock in lieu of cash. For the 2025 service year, each non-employee director will be automatically granted, in a lump-sum issuance, shares of restricted stock representing approximately $175.5 in value and will receive no cash payment for general Board of Director service beyond the $22.5 cash fee already paid to each director during the first quarter of 2025). For service years after 2025, each non-employee director will be automatically granted, in lump-sum issuances, shares of restricted stock representing approximately $90 in value (the “Annual Award”) and $117 in value (the “Election Award”). Both the Annual Award and the Election Award will generally vest over a three-year period; provided, however, that each non-employee director has the option to extend the vesting period of the Election Award to instead vest 100% at the end of a five-year period. Beginning with the 2026 calendar year, each non-employee director will have the option to elect to receive all, but not less than all, of the Election Award in the form of cash rather than shares of restricted stock. Each non-employee director who makes such election will receive a cash fee of $22.5 each quarter during such year.

On May 6, 2025, as part of the Company’s ongoing efforts to preserve cash, the Board of Directors of the Company approved (i) the issuance of unregistered shares of the Company’s common stock representing an aggregate of approximately $3,750 in value to the members of MedTech in lieu of the three remaining annual $1,250 cash payments otherwise required under the MedTech Purchase Agreement on or about May 1st of each of 2025, 2026, and 2027; and (ii) an Amended and Restated Non-Employee Director Compensation Policy that increases the total director compensation from approximately $180 to $207 per year and provides for the payment of the remaining director compensation for 2025 in shares of restricted stock in lieu of cash. For the 2025 service year, each non-employee director will be automatically granted, in a lump-sum issuance, shares of restricted stock representing approximately $175.5 in value and will receive no cash payment for general Board of Director service beyond the $22.5 cash fee already paid to each director during the first quarter of 2025). For service years after 2025, each non-employee director will be automatically granted, in lump-sum issuances, shares of restricted stock representing approximately $90 in value (the “Annual Award”) and $117 in value (the “Election Award”). Both the Annual Award and the Election Award will generally vest over a three-year period; provided, however, that each non-employee director has the option to extend the vesting period of the Election Award to instead vest 100% at the end of a five-year period. Beginning with the 2026 calendar year, each non-employee director will have the option to elect to receive all, but not less than all, of the Election Award in the form of cash rather than shares of restricted stock. Each non-employee director who makes such election will receive a cash fee of $22.5 each quarter during such year.